Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update Life Science Investing
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock Life Science Investing
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides Life Science Investing
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Life Science Investing
Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 Life Science Investing
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer Life Science Investing
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease Life Science Investing
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
